DE1793794A1 - PHARMACEUTICAL COMPOSITIONS - Google Patents

PHARMACEUTICAL COMPOSITIONS

Info

Publication number
DE1793794A1
DE1793794A1 DE19661793794 DE1793794A DE1793794A1 DE 1793794 A1 DE1793794 A1 DE 1793794A1 DE 19661793794 DE19661793794 DE 19661793794 DE 1793794 A DE1793794 A DE 1793794A DE 1793794 A1 DE1793794 A1 DE 1793794A1
Authority
DE
Germany
Prior art keywords
compositions according
group
denotes
steroid
unit contains
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE19661793794
Other languages
German (de)
Inventor
Derek Harold Richard Barton
Robert Hesse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Institute for Medicine and Chemistry Inc
Original Assignee
Research Institute for Medicine and Chemistry Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Institute for Medicine and Chemistry Inc filed Critical Research Institute for Medicine and Chemistry Inc
Publication of DE1793794A1 publication Critical patent/DE1793794A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

PatentansprücheClaims 1. Pharmazeutische Zusammensetzungen, enthaltend als aktiven Bestandteil eine oder mehrere Verbindungen der allgemeinen Formel1. Pharmaceutical compositions containing as active Component of one or more compounds of the general formula wobei Y ein Ketonsauerstoffatom oder eine in ein solches ttberführbare Gruppe, Z Hydroxy oder Fluor, Il einSauerstoffatom, das eine Bindung in die 11- oder 6-Stellung aufweist, R^ eine COCEUX-G-ruppe bedeutet, wobei X ein Wasserstoff- oder Halogenatom darstellt und R2 ein Wasserstoffatom oder eine Hydroxy- oder Acyloxygruppe bedeutet, oder R.. eine Hydroxygruppe und R« eine aliphatische Gruppe bedeutet, die gewünsentenfalls ein oder mehrere Halogenatome als Substituenten tragen kann, und R-, ist ein ß-aliminierbarer Substituent oder stellt eine Kohlenstoff-Kohlenstoffbindung dar, die in 4-Stellung gebunden ist, und/oder 19-A'ther und/oder 19-Ester des obigen Steroidhemiacetals.where Y is a ketone oxygen atom or a group that can be converted into such a group, Z is hydroxy or fluorine, II is an oxygen atom which has a bond in the 11- or 6-position, R 1 is a COCEUX-G group, where X is a hydrogen or halogen atom and R 2 denotes a hydrogen atom or a hydroxy or acyloxy group, or R .. denotes a hydroxyl group and R «denotes an aliphatic group which, if desired, can carry one or more halogen atoms as substituents, and R- is a β-aliminatable substituent or represents a carbon-carbon bond bonded in the 4-position and / or 19-ether and / or 19-ester of the above steroid hemiacetal. 2. Zusammensetzungen gemäß Anspruch 1,in Dosiseinheitsform.2. Compositions according to claim 1, in unit dosage form. 3. Zusammensetzungen gemäß Anspruch 2, worin jede Dosiseinheit 0,05 - 100 mg aktives Steroid enthält.3. Compositions according to claim 2, wherein each dosage unit contains 0.05-100 mg of active steroid. 4. Zusammensetzungen gemäß Anspruch 2, worin jede Dosiseinheit 0,1 - 50 mg aktives Steroid enthält.4. Compositions according to claim 2, wherein each dosage unit Contains 0.1 - 50 mg of active steroid. 5. Zusammensetzungen gemäß Anspruch 2, worin jede Dosiseinheit 1,0 - 25 mg aktives Steroid enthält.5. Compositions according to claim 2, wherein each dosage unit contains 1.0-25 mg of active steroid. 50 9831/083150 9831/0831 6. Zusammensetzungen gemäß einem der Ansprüche 1 - 5 in zur oralen Verabreichung angepaßter Form.6. Compositions according to any one of claims 1-5 for oral use Administration adapted form. 7* Zusammensetzungen gemäß Anspruch 6, in Form von Pastillen, Tabletten, Kapseln oder überzogenen Tabletten.7 * Compositions according to claim 6, in the form of troches, tablets, capsules or coated tablets. 8. Zusammensetzungen gemäß Anspruch 1 in Form von Sirups, Elixieren oder Emulsionen.8. Compositions according to claim 1 in the form of syrups, elixirs or emulsions. 9. Zusammensetzungen gemäß einem der Ansprüche 1-8, dadurch gekennzeichnet, daß die Träger oder Exzipienten in fester Form vorliegen oder sterile Flüssigkeiten oder Flüssigkeiten sind, die eines oder mehrere von Suspendier-, Emulgier-, Dispergier-, Verdickungs-, geschmacksgebenden, süßenden, Geruch erzeugenden oder Konservierungsmitteln enthalten.9. Compositions according to any one of claims 1-8, characterized in that the carriers or excipients are in solid form are present or are sterile liquids or liquids that contain one or more of suspending, emulsifying, dispersing, Contain thickeners, flavoring, sweetening, odor-producing or preservatives. 10. Zusammensetzungen gemäß einem der Ansprüche 1—9, dadurch gekennzeichnet, daß sie eine diuretische und/oder einen geringen Anteil an einer östrogenen oder proöstrogenen Substanz enthalten.10. Compositions according to any one of claims 1-9, characterized characterized in that they have a diuretic and / or a low proportion of an estrogenic or pro-estrogenic substance contain. 509831/0831509831/0831
DE19661793794 1965-12-17 1966-12-17 PHARMACEUTICAL COMPOSITIONS Pending DE1793794A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51469165A 1965-12-17 1965-12-17

Publications (1)

Publication Number Publication Date
DE1793794A1 true DE1793794A1 (en) 1975-07-31

Family

ID=24048303

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19661593348 Expired DE1593348C3 (en) 1965-12-17 1966-12-17 Process for the preparation of 19-fluoro-steroid epoxies and 19-fluoro-11,19-epoxy steroids
DE19661793794 Pending DE1793794A1 (en) 1965-12-17 1966-12-17 PHARMACEUTICAL COMPOSITIONS

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE19661593348 Expired DE1593348C3 (en) 1965-12-17 1966-12-17 Process for the preparation of 19-fluoro-steroid epoxies and 19-fluoro-11,19-epoxy steroids

Country Status (9)

Country Link
BE (1) BE691320A (en)
CH (1) CH587290A5 (en)
DE (2) DE1593348C3 (en)
DK (1) DK123407B (en)
FR (2) FR1511151A (en)
GB (1) GB1177648A (en)
IL (1) IL27072A (en)
NL (1) NL6617739A (en)
SE (1) SE348190B (en)

Also Published As

Publication number Publication date
SE348190B (en) 1972-08-28
CH587290A5 (en) 1977-04-29
IL27072A (en) 1972-07-26
FR6920M (en) 1969-05-05
DE1593348C3 (en) 1975-03-06
BE691320A (en) 1967-06-16
FR1511151A (en) 1968-01-26
DK123407B (en) 1972-06-19
DE1593348B2 (en) 1974-07-18
NL6617739A (en) 1967-06-19
DE1593348A1 (en) 1970-07-30
GB1177648A (en) 1970-01-14

Similar Documents

Publication Publication Date Title
DE69118494T2 (en) Contraception procedure and scheme
DE69118493T2 (en) Oral contraceptive with low estrogen content
EP1802376B1 (en) Transparent cosmetic or dermatological formulation
DE2621214C3 (en) Use of stabilizers in drugs with monoethyl fumarate and its mineral salts
DE312867T1 (en) GALLEN ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS THAT CONTAIN IT.
DE2447699C2 (en) Topical ointment base containing steroids
DE2704081A1 (en) MEDIUM WITH A SILICON DERIVATIVES CONTENT
DE2645307C2 (en)
DE3238984C2 (en)
DE1793794A1 (en) PHARMACEUTICAL COMPOSITIONS
EP0320437A3 (en) 17-methylene and 17-ethylidene estratrienes having an oestrogenic activity
WO2007096088A1 (en) Preparations effective against blemished skin and mild forms of acne with a content of hydroxymatairesinol as active principle
DE2434849A1 (en) HEART STRENGTHENING DOSING UNIT WITH A PREPARED CAPSULE
DE223671T1 (en) DRUGS WITH SYNERGISTIC ANTI-INFLAMMATORY EFFECT ON THE BASIS OF A CORTICOSTEROID AND A BETA AGONIST.
DE1617871A1 (en) Process for the production of a stable aqueous solution
DE2917979A1 (en) ORAL, STABLE, SOLID PHARMACEUTICAL COMPOSITION IN CAPSULE DOSING UNIT FOR THE FIGHT AGAINST FEARING CONDITIONS
DE2539824A1 (en) PHARMACEUTICAL PREPARATION
DE1792338B1 (en) Light stabilizers
DE3240044A1 (en) USE OF 17 (ALPHA) -ACYLOXY-6-METHYLPREGNA-4,6-DIEN-3,20-DIONES TO CONTROL BREAST CANCER
DE843285C (en) Light stabilizers
DE1667931C (en) Coronary insufficiency medicines
DE2059338A1 (en) Medicines based on cyproterone and its esters, as well as a method for the treatment of precocious puberty
DE1617818B2 (en) ORAL OR INJECTABLE ANTI-CONCEPTION AGENTS
Rösch Early carcinoma
AT205175B (en)